Abstract
Background: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.Methods: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.Results: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).Conclusions: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.
Highlights
Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, by disease stage and grade.N
Data were available for 4527 case patients and 6021 control subjects for blood selenium and for 1970 cases and 2086 controls for nail selenium
The duration of follow-up varied substantially; in some studies (Baltimore Longitudinal Study of Aging [BLSA], beta-Carotene and Retinol Efficacy Trial [CARET], MultiEthnic Cohort [MEC], Prostate, Lung, Colorectal and Ovarian Cancer Screening trial [PLCO], and Selenium and Vitamin E Cancer Prevention Trial [SELECT]), more than 70% of men were diagnosed less than five years following recruitment; in others (European Prospective Investigation into Cancer and NutritionHeidelberg [EPIC-Heidelberg], Netherlands Cohort Study [NLCS], Prostate Cancer Prevention Trial (PCPT), Physicians’ Health Study [PHS] and SU.VI.MAX), more than 70% of case patients were diagnosed five or more years after recruitment (Table 2)
Summary
The objective of the present study is to determine the association between blood and nail selenium concentration and risk of prostate cancer in 15 prospective studies and to evaluate this association by stage and grade of disease and other characteristics
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
